https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Adagene_Inc.Adagene Inc. - Revizia istoricului2026-04-26T19:18:44ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Adagene_Inc.&diff=404689&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Adagene Inc. listata cu simbolul US.ADAG ==Descriere companie== Adagene Inc (https://www.adagene.com/) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being develop...2024-09-18T13:35:08Z<p>Pagină nouă: Pagina dedicata companiei Adagene Inc. listata cu simbolul US.ADAG ==Descriere companie== Adagene Inc (https://www.adagene.com/) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being develop...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Adagene Inc. listata cu simbolul US.ADAG<br />
<br />
==Descriere companie==<br />
Adagene Inc (https://www.adagene.com/) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.ADAG" /><br />
<br />
==Ultimele stiri despre Adagene Inc. (US.ADAG)==<br />
<dynamicpagelist><br />
category=US.ADAG<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.ADAG]][[Categorie:Stiri despre companii]]</div>Admin